Latest News

£650K Investment in Oxford Photovoltaics, a Recent Oxford University Innovation Spin-out Company

27th July 2011

All News | Spinouts & Startups | Technology News

Isis welcomes the announcement from Oxford Photovoltaics Limited that it has completed a second funding round in 9 months.

Oxford’s Oxford University Innovation Expands in Asia

15th July 2011

All News | Technology News

Sixty leading names from the fields of technology, innovation and finance gathered at Club Lusitano, Hong Kong on Monday July 11 to mark the expansion of Oxford University Innovation Ltd. – the University of Oxford’s technology transfer arm – in Asia.

Isis-Saïd Business School Fellowships for 2011 Announced

14th July 2011

All News | Technology News

Isis and the Saïd Business School at the University of Oxford have awarded two new Fellowships for MBA graduates from the School, marking the fifth year of this successful and popular programme.

Oxyntix Ltd Spun-out of the University of Oxford by Oxford University Innovation with £1m Funding

7th July 2011

All News | Spinouts & Startups | Technology News

Oxyntix Ltd, a new company spun-out from the Department of Engineering Science at the University of Oxford by Oxford University Innovation Ltd., has completed an investment round of £1m.

Image from Symfo International and Oxford University Innovation Announce a Unique Turnkey Solution for Patient Reported Outcomes (PRO) Operations News Article

Symfo International and Oxford University Innovation Announce a Unique Turnkey Solution for Patient Reported Outcomes (PRO) Operations

29th June 2011

All News | Technology News

Isis Outcomes, a part of Oxford University Innovation Ltd, and Symfo are applying their respective areas of expertise to offer Sponsors and CRO1s a unique service that will help Drug Development/Study Managers to assess and choose the right PRO2 measure – validating and deploying PRO instruments, and ensuring that the study will meet Regulatory Authorities requirements.

Diagnostic test for a rare form of cancer developed by Oxford researchers

14th June 2011

All News | Technology News

Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a disorder that causes the development of benign but often painful tumours in the skin and, in females, in the uterus. Between one in six and one in ten people affected by the disorder will go on to develop an aggressive form of kidney cancer called papillary renal cell cancer. The condition often strikes people in their 20s.

Technology from Oxford Will Provide Environmentally Friendly Replacement for Lithium Batteries

12th May 2011

All News | Technology News

Edman Tsang of Oxford University’s Department of Chemistry and colleagues are developing new catalysts which can produce hydrogen at room temperature without the need for solvents or additives.

New Language Versions of the Endometriosis Health Profile (EHP) Added to Isis Outcomes PRO Library

10th May 2011

All News | Clinical Outcomes | Technology News

Sixteen new language versions have been completed by Oxford Outcomes Ltd, a research agency specialising in the translation and linguistic validation of patient reported outcome (PRO) measures.

Milestone in clinical trial of improved TB vaccine developed in Oxford

4th May 2011

All News | Technology News

The two thousand, seven hundred and eighty-fourth baby has been vaccinated in South Africa as part of a clinical trial of a new vaccine against tuberculosis. The new TB vaccine is the most advanced in development anywhere in the world.

Oxford Nanopore Technologies Announce £25m Fundraising

28th April 2011

All News | Technology News

Oxford Nanopore Technologies has licensed or owns more than 250 patents and patent applications that relate to many aspects of nanopore sensing from protein nanopores to solid state nanopores and for the analysis of DNA, proteins and other molecules.

News

Ready to get in touch?